Form 8-K - Current report:
SEC Accession No. 0001279569-25-000469
Filing Date
2025-05-08
Accepted
2025-05-08 07:04:05
Documents
15
Period of Report
2025-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K form8k.htm   iXBRL 8-K 24821
2 PRESS RELEASE DATED MAY 8, 2025 ex991.htm EX-99.1 41965
3 GRAPHIC logo.jpg GRAPHIC 10685
  Complete submission text file 0001279569-25-000469.txt   262787

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE epix-20250508.xsd EX-101.SCH 3020
5 XBRL LABEL FILE epix-20250508_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE epix-20250508_pre.xml EX-101.PRE 22362
18 EXTRACTED XBRL INSTANCE DOCUMENT form8k_htm.xml XML 3772
Mailing Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5
Business Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5 (778) 331-0962
ESSA Pharma Inc. (Filer) CIK: 0001633932 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37410 | Film No.: 25923803
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)